Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Emergency Medical Resuscitation Kit Use – V 2.0

Posted on By

BA-BE Studies: SOP for Emergency Medical Resuscitation Kit Use – V 2.0

Standard Operating Procedure for Emergency Medical Resuscitation Kit Use in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/136/2025
Supersedes SOP/BA-BE/136/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for maintaining and using the Emergency Medical Resuscitation Kit at clinical sites conducting BA/BE studies in order to ensure immediate availability and proper use of life-saving equipment and medication during medical emergencies.

2. Scope

This SOP applies to all clinical research sites and medical personnel involved in conducting BA/BE trials where human subjects may require urgent medical resuscitation

following adverse reactions, dosing events, or unexpected health crises.

3. Responsibilities

  • Medical Officer: Responsible for proper use of the resuscitation kit during emergencies and maintaining readiness.
  • Study Nurse: Assists in using kit components and documents post-use actions.
  • Clinical Coordinator: Conducts monthly inspection and replenishment of the resuscitation kit.
  • QA Officer: Verifies inspection records and compliance during audits.
See also  BA-BE Studies: SOP for Volunteer Compensation and Reimbursement - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring that a fully stocked and functional resuscitation kit is available at all times during the clinical conduct of the study.

5. Procedure

5.1 Kit Location and Accessibility

  1. Place the resuscitation kit in a visible and easily accessible area near the dosing and observation rooms.
  2. Affix signage labeled “EMERGENCY RESUSCITATION KIT” above the kit’s location.

5.2 Resuscitation Kit Contents

  1. Essential equipment and medication (see Annexure-1) must include:
    • Bag-valve mask (adult)
    • Oxygen cylinder with flowmeter and tubing
    • Defibrillator (AED or manual)
    • Syringes, IV sets, saline
    • Medications: adrenaline, antihistamines, corticosteroids, atropine
    • Glucometer and dextrose solution

5.3 Usage of Resuscitation Kit During Emergency

  1. Immediately transport the kit to the patient’s bedside upon detection of emergency signs (e.g., unconsciousness, respiratory distress).
  2. Medical Officer must:
    • Assess airway, breathing, and circulation (ABCs)
    • Administer oxygen and appropriate medication based on diagnosis
    • Use defibrillator if cardiac arrest is detected
  3. Document actions in Annexure-2: Emergency Intervention Log.
See also  BA-BE Studies: SOP for Emergency Medical Handling in BE Units - V 2.0

5.4 Inspection and Replenishment

  1. Inspect the kit monthly or after each use.
  2. Use Annexure-3: Resuscitation Kit Inspection Checklist to verify:
    • Availability of items
    • Expiry dates of drugs
    • Functionality of equipment
  3. Replace expired/used items within 24 hours.

5.5 Training Requirements

  1. All medical and paramedical staff must undergo annual BLS/ACLS training.
  2. Training attendance to be recorded in Annexure-4: Resuscitation Training Record.

6. Abbreviations

  • BLS: Basic Life Support
  • ACLS: Advanced Cardiovascular Life Support
  • QA: Quality Assurance
  • PI: Principal Investigator

7. Documents

  1. Resuscitation Kit Contents List – Annexure-1
  2. Emergency Intervention Log – Annexure-2
  3. Resuscitation Kit Inspection Checklist – Annexure-3
  4. Resuscitation Training Record – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
  • American Heart Association BLS/ACLS Guidelines
See also  BA-BE Studies: SOP for Informed Consent Process Execution - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Resuscitation Kit Contents List

Item Quantity Expiry Date Status
Adrenaline 1 mg/mL 5 ampoules 30/06/2025 Available
Bag-Valve Mask 1 N/A Functional

Annexure-2: Emergency Intervention Log

Date Subject ID Event Medication Given Outcome
16/04/2025 SUB009 Syncope Oxygen, IV fluids Recovered

Annexure-3: Resuscitation Kit Inspection Checklist

Date Inspected By Expiry Check Functional Check Remarks
15/04/2025 Sunita Reddy All valid OK No issues

Annexure-4: Resuscitation Training Record

Employee Name Designation Date of Training Trainer Remarks
Ajay Verma Nurse 10/03/2025 Dr. Meena Joshi Certified

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release Site preparedness policy QA Head
17/04/2025 2.0 Added training and intervention logging procedures Audit CAPA requirement QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Flame Test Method Development – V 2.0
Next Post: Biosimilars: SOP for Inoculation of Shake Flasks – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version